Quantcast

World Biological Drugs Market 2013-2023

October 29, 2013

Reportbuyer.com just published a new market research report: World Biological Drugs Market 2013-2023.

London (PRWEB) October 29, 2013

Report Details

Biologics – discover and assess products with highest revenue potential

Do you want to find sales potentials of biological drugs? Visiongain's updated report gives you revenue predictions for biologics from 2013, helping you stay ahead. There you find financial data, R&D trends, opportunities, and discussions of prospects.

In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging trends, technologies, and expected products.

You see what shapes the biologics industry, discovering its commercial potential

Discover, then, what the future holds for biologics (biologicals). Read on to see features of the biopharma industry and discover what its future market could be worth.

Forecasts and other analyses show you trends and best prospects

Besides revenue forecasting to 2023, you find historical data, growth rates, and market shares. There you assess quantitative and qualitative analysis, news, outlooks, and developments (R&D). You also gain 174 tables, 129 charts, and four research interviews.

Many opportunities remain for biological drugs, because of their increasing use. Our study shows you the most lucrative parts of that market, helping you stay ahead. Now see how you can benefit your research, analyses and decisions.

Finding data you need has just got easier. The following sections show how you benefit from our new analysis.

Discover sales predictions for the world biologics market and its submarkets

Along with revenue prediction for the overall world market for biological drugs, our work shows forecasts from 2013 to 2023 for individual submarkets:

•Protein therapeutics – with sub forecasts for insulins, other recombinant hormones, plasma and recombinant coagulating factors, interferons, and other agents

•Monoclonal antibodies (mAbs) – with sub forecasts for autoimmune, anticancer, and other agents

•Fusion proteins

•Cellular and regenerative medicines – with sub forecasts for tissue-engineered products, cellular therapies, and gene therapy.

Our report shows you revenue potentials of biopharmaceuticals, helping you find opportunities to develop your business.

Also our investigation discusses what stimulates and restrains sales of biotechnological medicines. There you explore that industry, seeing what products can achieve the most success.

Discover sales forecasts for prominent brands

Our new study forecasts revenues of 13 leading products, including these:

•Lantus

•Epogen

•Avonex

•NovoRapid

•Humira

•Remicade

•Rituxan

•Herceptin

•Avastin.

There you discover how high sales can go, to 2023, with individual forecasts. You see what's happening, understanding trends, competition, challenges, and opportunities.

The report also divides its overall world forecast into those for geographical regions.

Leading national markets – where will highest revenues and growth occur?

Developments worldwide will influence the biologicals market, especially rising demand in developed and developing countries. Find progress and opportunities there.

Our analyses show you individual revenue forecasts to 2023 for eleven national markets:

•United States (US)

•Japan

•EU leaders – Germany, France, the UK, Italy, and Spain (EU5)

•BRIC countries – Brazil, Russia, India, and China.

There you discover prospects and potential sales. You assess the biological drug industry's future -hear about developments and find their significance. In particular, drug launches will change medical prescribing from 2013 to 2023.

Research and development – you see trends and possibilities for new therapies

What about R&D – the pipeline for new drugs? You see trends for these agents:

•Insulins and other recombinant hormones

•Plasma and recombinant coagulating factors

•Interferons and other protein therapeutics

•Rheumatoid arthritis (RA), other autoimmune, and asthma mAbs

•Multiple sclerosis (MS), lupus, and psoriasis mAbs.

Our study also discusses these biotechnologies in development:

•Cancer (oncology) and cardiovascular mAbs

•Alzheimer's disease, ophthalmic, and anti-infective mAbs

•Fusion proteins

•Tissue-engineered products

•Cellular therapies

•Gene therapy.

R&D for biological drugs holds strength, variety, and promise. You assess innovations, hearing about developments and finding their significance. Discover progress.

In particular, mAbs and fusion proteins hold potential, with more than 25 late-stage candidates and several emerging technologies.

Anyhow, for large companies and specialty pharma firms, there exist many therapeutic and commercial opportunities. Our study explains. See, then, what the future holds.

Leading companies and 2017 market value

From 2013, product launches there hold great potential for investment, uptake, and revenues. Our study predicts the world market for biologics will reach $178.4bn in 2017, with further growth to 2023. See how high revenues can go.

There you assess what biopharma technologies, products types, and companies hold most potential. Our analyses cover these and many other developers and producers:

•Roche

•Amgen

•Novo Nordisk

•AbbVie

•Johnson & Johnson.

In our report you find 284 organisations mentioned. Also, you read four interviews with other authorities. Find out what shapes the industry.

R&D for biologicals is strong, and from 2013 there will arise many opportunities. There are prospects for new drugs and overall sales growth. Our work shows the possibilities, helping you stay ahead.

Nine ways World Biological Drugs Market 2013-2023 helps you

In particular, then, our investigation gives you the following knowledge:

•Revenue to 2023 for the world biologics market – discover that industry's overall sales prospects

•Revenues to 2023 for 15 world-level submarkets – investigate the potential of its components, finding the most promising places for investments and revenues

•Prospects to 2023 for 13 leading products – see revenue forecasts for top brands

•Forecasts to 2023 for 11 leading national markets in the Americas, Europe, and Asia – discover the best regions and countries for revenues and potential growth

•Activities of leading companies – hear about participants' actions, capabilities, results, and outlooks

•Charting and discussions of R&D – explore progress in the biological drugs industry, finding technological, medical, and commercial possibilities

•Interviews with other experts on biologicals – discover what authorities in that field think, say, and do, helping you stay ahead

•Competition and opportunities – investigate what shapes that market's future, including ways to develop business

•Analysis of what stimulates and restrains the biopharma market – assess challenges and strengths, helping you compete and gain advantages.

You gain information found nowhere else

That work gives independent analysis. There you receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our new study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions, also saving time.

Discover potential now in the biologics market and find what you can gain.

For biologics, see commercial prospects from 2013 by ordering now

Our investigation is for everyone analysing the industry and market for biological drugs. There you find data, trends, opportunities, and predictions. Please order that report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

Table of Contents

1. Executive Summary

1.1 World Biological Drugs Market Review

1.2 Summary of Report Contents

1.3 Research and Analysis Methods

2. Biological Drugs Market: Clinical and Commercial Overview, 2013-2023

2.1 Biologics Market Projections for 2013-2023

2.2 The Importance of Biological Drugs to the Global Pharmaceutical Market

2.2.1 Defining 'Biological'

2.2.2 Biological Drugs Constituted 15% of the Global Pharmaceutical Market in 2012

2.2.2.1 The Leading Biological Products and How they Rank Overall

2.2.2.2 Why are Biologics the Most Lucrative Pharmaceutical Products in the Global Market Overall?

2.2.3 The Biosimilars Revolution: Coming Soon?

2.2.3.1 Biosimilars Represented Just Over 1% of the Biologics Market in 2012

2.2.3.2 An Important Decade for Biosimilars

2.2.4 Autoimmune Diseases, Cancer and Diabetes Treatments Make Up 73% of the Biologics Market

2.2.4.1 Other Therapeutic Areas within the Biologics Market

2.2.4.2 How the Biologics Market's Therapeutic Focus Differs from the Broader Pharmaceutical Market

2.2.5 Roche Still Leads the Biologics Market

2.3 Overview of the Four Submarkets, 2013-2023

2.3.1 Superior Pipeline Will Drive Increased Market Share for MAbs Submarket

2.4 Protein Therapeutics Submarket: Scientific and Historical Background

2.4.1 Proteins Have Been Used Medicinally Since the 19th Century

2.4.2 Recombinant DNA Technology

2.4.3 Biotechs and Biotechnology

2.4.4 Insulin: The First Protein Therapeutic

2.4.5 Approval of Recombinant Hormones

2.4.6 Discovery of Plasma and Clotting Proteins

2.4.7 Interferons Approved in 1990s

2.4.8 Other Protein Therapeutics

2.5 MAbs Submarket: Scientific and Historical Background

2.5.1 Natural Antibodies: Key to the Immune System

2.5.2 From Serum Therapy to Monoclonal Antibodies (MAbs)

2.5.3 Humanising the MAb

2.5.4 MAbs for Autoimmune Indications

2.5.5 MAbs for Cancer Indications

2.5.6 MAbs for Other Therapeutic Area Indications

2.5.7 MAbs for All? The Technology Comes Off Patent

2.5.8 Next-Generation Technologies

2.6 Fusion Proteins Submarket: Scientific and Historical Background

2.6.1 Differentiating Fusion Proteins

2.7 Cellular and Regenerative Medicines Submarket: Scientific and Historical Background

2.7.1 Tissue Engineering

2.7.2 Cellular Therapies

2.7.3 Gene Therapy

2.8 Marginal Cases

2.8.1 The Vaccines Market

3. Protein Therapeutics Submarket, 2013-2023

3.1 Protein Therapeutics Submarket Projections for 2013-2023

3.2 Protein Therapeutics Submarket: Breakdown by Segment, 2013-2023

3.2.1 Insulins Segment: Set to Grow Rapidly to 2023

3.2.1.1 Novo Nordisk, Sanofi and Eli Lilly Dominate the Insulins Segment

3.2.1.2 Duration of Action the Major Differentiator for Insulins

3.2.1.3 Tresiba: A Game-Changer for the Segment?

3.2.1.4 Pegylated Insulins, Ultra-Concentrated Insulins, and Insulin Tablets: Insulin Pipeline for the Big Three

3.2.1.5 Biosimilars and Other Insulins in Development

3.2.1.6 Diabetes Prevalence the Major Driver for Insulins

3.2.1.7 Market Forecast for Insulins Segment, 2013-2023

3.2.2 Other Recombinant Hormones: Set for Biosimilar Competition

3.2.2.1 Revenues for Erythropoietins Continue to Fall in 2012

3.2.2.2 Biosimilars, Safety Concerns and Other Restraints for Erythropoietins

3.2.2.3 G-CSF: How Long Can Amgen and Kyowa Continue to Dominate?

3.2.2.4 Biosimilar Filgrastim and Pegfilgrastim to Reach All the Major Regional Markets

3.2.2.5 Somatropin: Another Well-Established Recombinant Hormone

3.2.2.6 Biosimilar and Safety Challenges to Growth Hormones

3.2.2.7 Pipeline for Other Recombinant Hormones

3.2.2.8 Drivers and Restraints for Other Recombinant Hormones

3.2.2.9 Market Forecast for Other Recombinant Hormones Segment, 2013-2023

3.2.3 Plasma and Recombinant Coagulating Factors: A Growth Opportunity

3.2.3.1 Types of Recombinant Factor

3.2.3.2 Key Clotting Factor Deficiency Diseases

3.2.3.3 Six Companies Dominate the Segment

3.2.3.4 Other Companies Targeting this Segment: Biogen Idec Leads the Pack

3.2.3.5 Extended Duration of Action to be a Differentiator

3.2.3.6 Limited Opportunities for Biosimilar Challenges

3.2.3.7 Other Pipeline Developments

3.2.3.8 Drivers and Restraints for Plasma and Recombinant Coagulating Factors, 2013

3.2.3.9 Market Forecast for Plasma and Recombinant Coagulating Factors Segment, 2013-2023

3.2.4 Interferons: Two Decades as Key Antiviral and MS Therapeutics

3.2.4.1 Leading Interferon Brands in 2012

3.2.4.2 Interferons Remain Part of Hepatitis Standard of Care Despite Severe Limitations

3.2.4.3 How Will Interferons Compete Against the Pipeline Protease and Polymerase Inhibitors?

3.2.4.4 Aubagio, Tecfidera and Lemtrada to Reduce Interferons' Hold on the MS Therapeutic Area

3.2.4.5 Biosimilar First-Generation Interferons Widely Available in Emerging Markets

3.2.4.6 Can the Pipeline Rejuvenate the Interferons Segment?

3.2.4.7 Drivers and Restraints for the Interferons Segment, 2013

3.2.4.8 Market Forecast for Interferons Segment, 2013-2023

3.2.5 Other Protein Therapeutics: Enzyme Replacement A Key Area

3.2.5.1 Pipeline for Other Protein Therapeutics

3.2.5.2 Market Forecast for Other Protein Therapeutics Segment, 2013-2023

3.3 Leading Products in the Protein Therapeutics Submarket, 2013-2023

3.3.1 Changing Market Shares, 2013-2023

3.3.2 Lantus (Sanofi), 2013-2023

3.3.2.1 Tresiba's Cardiovascular Concerns Mean Lantus Will Stay In Front

3.3.2.2 Market Forecast for Lantus, 2013-2023

3.3.3 Neulasta/Neupogen (Amgen), 2013-2023

3.3.3.1 Biosimilars the Main Concern for Amgen

3.3.3.2 Market Forecast for Neulasta/Neupogen, 2013-2023

3.3.4 Epogen (Amgen), 2013-2023

3.3.4.1 Amgen's Defence of Epogen's Market Share

3.3.4.2 Market Forecast for Epogen, 2013-2023

3.3.5 Avonex (Biogen Idec), 2013-2023

3.3.5.1 How Will Avonex Fare in the Changing MS Therapeutic Area?

3.3.5.2 Market Forecast for Avonex, 2013-2023

3.3.6 NovoRapid (Novo Nordisk), 2013-2023

3.3.6.1 Competition in the Short-Acting Insulin Analogues Market

3.3.6.2 Market Forecast for NovoRapid, 2013-2023

3.3.7 Other Products, 2013-2023

3.3.7.1 Major Future Approvals in this Submarket

3.3.7.2 Market Forecast for Other Products, 2013-2023

3.4 Leading Products in Development in the Protein Therapeutics Submarket, 2013

3.4.1 Recombinant Factor XIII (Novo Nordisk)

3.4.2 NN7008 (Novo Nordisk)

3.4.3 Liprotamase (Eli Lilly)

3.4.4 IDegLira (Novo Nordisk)

3.4.5 LY2605541 (Eli Lilly / Boehringer Ingelheim)

3.4.6 LY2963016 (Eli Lilly / Boehringer Ingelheim)

3.4.7 FIAsp (Novo Nordisk)

3.4.8 Somatropin (LG Life Sciences)

3.4.9 Natpara (NPS Pharmaceuticals)

3.4.10 Recombinant von Willebrand Factor (Baxter)

3.4.11 IB1001 (Inspiration Biopharmaceuticals)

3.4.12 NN7088 (Novo Nordisk)

3.4.13 NN7999 (Novo Nordisk)

3.4.14 Recombinant Factor VIII Fc (Biogen Idec)

3.4.15 Recombinant Factor IX Fc (Biogen Idec)

3.4.16 BAY 94-9027 (Bayer)

3.4.17 Human Recombinant Factor VIII (Octapharma)

3.4.18 OBI-1 (Inspiration Biopharmaceuticals)

3.4.19 BIIB017 (Biogen Idec)

3.4.20 Alferon N Injection (HemispherX Biopharma)

3.4.21 PEG-interferon Lambda (Bristol-Myers Squibb)

3.4.22 NU-100 (Nuron Biotech)

3.4.23 Multikine (CEL-SCI)

3.4.24 Talactoferrin Alpha (Agennix)

3.4.25 Desmoteplase (Lundbeck)

3.4.26 Mycobacterium Cell Wall-DNA complex (Bioniche Therapeutics)

4. Monoclonal Antibodies Submarket, 2013-2023

4.1 Monoclonal Antibodies Submarket Projections for 2013-2023

4.2 Monoclonal Antibodies Submarket: Breakdown by Segment, 2013-2023

4.2.1 Autoimmune MAbs: Leading Segment of Biologics Market in 2012

4.2.1.1 Humira and Remicade Dominate Autoimmune MAbs Segment

4.2.1.2 TNF Blockers Represent 79% of All Revenues in the Autoimmune Segment

4.2.1.3Johnson & Johnson Leads the Autoimmune Segment with 41% Market Share

4.2.1.4 The Autoimmune MAbs Pipeline

4.2.1.5 Asthma and Lupus Next Behind RA as R&D Focus for Autoimmune MAbs

4.2.1.6 Competition for the Autoimmune MAbs

4.2.1.7 Drivers and Restraints for Autoimmune MAbs, 2013

4.2.1.8 Market Forecast for Autoimmune MAbs Segment, 2013-2023

4.2.2 Oncology MAbs: Focus for Next-Generation Antibody Innovation

4.2.2.1 Roche's Three Major Products Dominate the Segment

4.2.2.2 Perjeta and Kadcyla Will Cement the Importance of HER2 as Key Molecular Target

4.2.2.3 Eight Approved MAbs Target Haematological Cancers

4.2.2.4 Bristol-Myers Squibb Rank Second in Oncology Segment

4.2.2.5 Next-Generation Formats Bolster Extensive Oncology Pipeline

4.2.2.6 Solid Tumours are the Major Challenge for Oncology MAbs

4.2.2.7 Drivers and Restraints for Oncology MAbs, 2013

4.2.2.8 Market Forecast for Oncology MAbs Segment, 2013-2023

4.2.3 Other Therapeutic Areas MAbs: New Breakthroughs to Come?

4.2.3.1 Lucentis Continues to Dominate this Segment

4.2.3.2 Pipeline Targets Several New Therapeutic Areas

4.2.3.3 Anti-PCSK9 MAbs to Combine with Statins?

4.2.3.4 After Bapineuzumab: New Hope for Alzheimer's MAbs

4.2.3.5 Building on Lucentis: MAbs for Ophthalmic Indications

4.2.3.6 Anti-Infective MAbs: The New Antibiotics?

4.2.3.7 Drivers and Restraints for Other Therapeutic Areas MAbs, 2013

4.2.3.8 Market Forecast for Other Therapeutic Areas MAbs Segment, 2013-2023

4.3 Leading Products in the MAbs Submarket, 2013-2023

4.3.1 Changing Market Shares, 2013-2023

4.3.2 Humira (AbbVie), 2013-2023

4.3.2.1 Approved for Ulcerative Colitis, but will Oral RA Treatments Threaten Humira?

4.3.2.2 Market Forecast for Humira, 2013-2023

4.3.3 Remicade (Johnson & Johnson), 2013-2023

4.3.3.1 Can Remicade Survive the Biosimilar Challenge from Korea?

4.3.3.2 Market Forecast for Remicade, 2013-2023

4.3.4 Rituxan (Roche), 2013-2023

4.3.4.1 Battle for the CD20 Market: Rituxan vs The Rest

4.3.4.2 Market Forecast for Rituxan, 2013-2023

4.3.5 Herceptin (Roche), 2013-2023

4.3.5.1 The First Major PLM Strategy in the MAb Submarket: Herceptin, Perjeta and Kadcyla

4.3.5.2 Market Forecast for Herceptin, 2013-2023

4.3.6 Avastin (Roche), 2013-2023

4.3.6.1 Is Avastin Reaching its Limits?

4.3.6.2 Market Forecast for Avastin, 2013-2023

4.3.7 Other MAb Products, 2013-2023

4.3.7.1 Forecast for Other MAb Products, 2013-2023

4.4 Leading Products in Development in the MAbs Submarket, 2013

4.4.1 CNTO-136 (Johnson & Johnson)

4.4.2 Daclizumab (AbbVie/Biogen Idec)

4.4.3 Epratuzumab (UCB/ Immunomedics)

4.4.4 Ocrelizumab (Biogen Idec/ Roche)

4.4.5 Sarilumab (Sanofi)

4.4.6 Secukinumab (Novartis)

4.4.7 Tabalumab (Eli Lilly)

4.4.8 Ixekizumab (Eli Lilly)

4.4.9 Tanezumab (Pfizer)

4.4.10 Mepolizumab (GlaxoSmithKline)

4.4.11 Reslizumab (Cephalon)

4.4.12 Lebrikiuzmab (Genentech)

4.4.13 Tildrakizumab (Merck)

4.4.14 ch14.18 (United Therapeutics)

4.4.15 Inotuzumab Ozogamicin (Pfizer)

4.4.16 Elotuzumab (Bristol-Myers Squibb)

4.4.17 Farletuzumab (Eisai)

4.4.18 Ganitumab (Amgen)

4.4.19 MABp1 (Xbiotech)

4.4.20 GA101 (Roche)

4.4.21 Mogamalizumab (Kyowa Hakko Kirin)

4.4.22 Necitumumab (Eli Lilly)

4.4.23 Nivolumab (Bristol-Myers Squibb)

4.4.24 Onartuzumab (Roche)

4.4.25 Ramucirumab (Eli Lilly)

4.4.26 Girentuximab (Wilex)

4.4.27 AMG145 (Amgen)

4.4.28 SAR 236553 (Sanofi/ Regeneron)

4.4.29 Gevokizumab (XOMA)

4.4.30 Teplizumab (MacroGenics)

4.4.31 Anthraximmune Globulin (Cangene)

4.4.32 Actoxumab (Merck)

4.4.33 Romosozumab (Amgen)

4.4.34 Solanezumab (Eli Lilly)

5. Fusion Proteins Submarket, 2013-2023

5.1 Fusion Proteins Submarket Projections for 2013-2023

5.2 Leading Products in the Fusion Proteins Submarket, 2013-2023

5.2.1 New Approvals to Drive Submarket Growth to 2023

5.2.2 Enbrel (Amgen): Leading Fusion Protein, 2013

5.2.2.1 Biosimilar Enbrel Competitors on Hold?

5.2.2.2 Market Forecast for Enbrel, 2013-2023

5.2.2.3 Can Orencia Differentiate Itself in the RA Market?

5.2.3 Eylea (Regeneron): Breaking Into the AMD Market in 2012

5.2.3.1 Scope for Expansion with Eylea

5.2.3.2 Market Forecast for Eylea, 2013-2023

5.2.4 Other Fusion Proteins, 2013-2023

5.3 Leading Products in Development in the Fusion Proteins Submarket, 2013

5.3.1 Albiglutide (GlaxoSmithKline)

5.3.2 Dulaglutide (Eli Lilly)

5.3.2.1 Could the Fifth in Class Become the Best in Class?

5.3.3 Atacicept (Merck KGaA/ZymoGenetics)

5.3.4 AMG 386 (Amgen)

6. Cellular and Regenerative Medicines Submarket, 2013-2023

6.1 Cellular and Regenerative Medicines Submarket Projections for 2013-2023

6.2 Cellular and Regenerative Medicines Submarket: Breakdown by Segment, 2013-2023

6.2.1 Tissue Engineered Products: Prospects Beyond Wound Repair?

6.2.1.1 Apligraf Leads the Tissue Engineered Products Segment in 2013

6.2.1.2 Apligraf Competes with Dermagraft in Diabetic Foot Ulcers Therapeutic Area

6.2.1.3 Other Potential Applications for Tissue Engineering

6.2.1.4 Drivers and Restraints for the Tissue Engineered Products Segment, 2013

6.2.1.5 Market Forecast for Tissue Engineered Products Segment, 2013

6.2.2 Cellular Therapies Segment, 2013-2023

6.2.2.1 Approvals in Canada and South Korea Bolster Stem Cell Field

6.2.2.2 The Big Stem Cell Breakthrough I: The New Wave of MSC Treatments

6.2.2.3 The Big Stem Cell Breakthrough 2: Regenerating Organs

6.2.2.4 Chondrocytes for Cartilage Repair

6.2.2.5 Drivers and Restraints for Cellular Therapies, 2013

6.2.2.6 Market Forecast for Cellular Therapies, 2013-2023

6.2.3 Gene Therapy: Has the Time Come at Last for This Technology?

6.2.3.1 Existing Gene Therapy Products: Asian Approvals

6.2.3.2 Glybera Brings Gene Therapy to Europe

6.2.3.3 Significant Pipeline for Gene Therapies

6.2.3.4 Drivers and Restraints for Gene Therapy, 2013

6.2.3.5 Market Forecast for Gene Therapy, 2013-2023

6.3 Leading Products in Development in the Cellular and Regenerative Medicines Submarket, 2013

6.3.1 CAIS (Depuy Mitek)

6.3.2 Neocart (Histogenics Corporation)

6.3.3 Ixmyelocel-T (Aastrom Biosciences)

6.3.4 "Off-the-shelf" Mesenchymal Precursors (Mesoblast)

6.3.4.1 Gamida Cell Competing for this Market Opportunity

6.3.5 Prochymal (Osiris Therapeutics)

6.3.6 Auto-CD34+ Cells (Baxter)

6.3.6.1 NeoStem vs Baxter

6.3.7 Cx601 (Tigenix)

6.3.8 Talminogene Laherparepvec (Amgen)

6.3.9 Generx (Cardium Therapeutics)

7. Leading National Markets for Biological Drugs, 2013-2023

7.1 The US Remained the Largest Market in 2012

7.2 Overview of Market Change, 2013-2023

7.3 Breakdown by Region, 2013-2023

7.3.1 US, 2013-2023

7.3.1.1 US Health Spending Nears $3 Trillion

7.3.1.2 Value-Based Pricing in the US

7.3.1.3 US Regulation of Biologics

7.3.1.4 Biologics Price Competition and Innovation Act

7.3.1.5 Market Forecast for the US, 2013-2023

7.3.2 EU5, 2013-2023

7.3.2.1 European Leadership on Biosimilars

7.3.2.2 Other Biosimilar Regulations

7.3.2.3 Market Forecast for EU5, 2013-2023

7.3.2.4 Breakdown of the EU5, 2013-2023

7.3.3 Japan, 2013-2023

7.3.3.1 Sandoz and JCR Pioneering Japanese Biosimilars

7.3.3.2 Market Forecast for Japan, 2013-2023

7.3.4 BRIC Nations, 2013-2023

7.3.4.1 Market Forecast for the BRIC Nations, 2013-2023

7.3.4.2 Brazil: Government to Take the Lead in Biologics Manufacture?

7.3.4.3 Russia: Targeting Domestic Biomanufacturing Capacity

7.3.4.4 India: Will the Generics Hub Become the Biosimilars Leader?

7.3.4.5 China: The Major Market Opportunity

7.3.4.6 Breakdown of the BRIC Nations, 2013-2023

8. Qualitative Industry Analysis: Drivers and Restraints, 2013

8.1 Strengths: An Established and Successful Market

8.2 Weaknesses: Has the Advance of Biopharmaceuticals Reached its Limits?

8.3 Opportunities: Time for a New Phase in the Biologics Revolution

8.4 Threats: Where Will the Innovations Needed to Keep the Market Moving Come From?

8.5 Social Factors: How Much Do Physicians and Patients Want the New Biologics?

8.6 Technological Developments: Crucial to the Market

8.7 Economic Pressures: A Constant Theme in the Biologics Market

8.8 Political Issues: Governments Shaping the Regulatory Future of the Market

9. Research Interviews

9.1 Overview of the Biotech Industry in 2013: Interview with Ronald A. Rader, President of Biotechnology Information Institute

9.1.1 Steady Growth, but a Dearth of New Blockbusters

9.1.2 The Price of Biological Drugs

9.1.3 Biosimilars to Outnumber Innovator Products

9.1.4 'Differentiated Biologics': Biosimilars vs Bio-Betters

9.1.5 Changing of the Guard: Can New Classes of Biopharmaceuticals Transform the Market?

9.1.6 Big Pharma and the Biotechs

9.1.7 Bundled Payments and Bulked-up Portfolios, and Other Reasons Why Every Major Player Will Get Involved in Biosimilars

9.1.8 Modular Bioprocessing: The Next Revolution?

9.2 Next-Generation MAbs: Interview with Dr Janice Reichert

9.2.1 On Antibody-Drug Conjugates

9.2.2 On Engineered Improvements to Antibodies

9.2.3 On the Current Scientific Understanding of Antibody Functions

9.2.4 On Bispecific Antibodies

9.2.5 On Antibody Fragments and Market Pricing

9.2.6 On the Overall Prospects for Next-Generation Antibodies

9.3 MAb vs. Fusion Protein in the AMD Market: Interview with Dr Michael Stewart, Mayo Clinic

9.3.1 The Impact of Eylea, 2011-2012

9.3.2 The Comparative Dosing Schedules of Eylea and Lucentis

9.3.3 Patient Transitioning to Eylea: Salvage Switching

9.3.4 Avastin After the CATT Study

9.3.5 Prospects for Eylea in Other Indications and Combinations

9.3.6 Future Possibilities in Wet AMD Treatment

9.4 A Revolution in Regenerative Medicine? Interview with Dr Alan Trounson, President, California Institute for Regenerative Medicine (CIRM)

9.4.1 Current Stem Cell Clinical Trials

9.4.2 Big Pharma Investment in Stem Cells

9.4.3 Mesenchymal Cells in Clinical Trials

9.4.4 On Definitions of Cell Types and Regulatory Pathways

9.4.5 The Prospects for Stem Cell Cures

10. Conclusions

10.1 The Biologics Market Will Grow in Importance for the Pharmaceuticals Industry

10.2 MAbs and Protein Therapeutics Will Continue to Be the Dominant Submarkets

10.3 Biosimilars Will Transform the Market

10.4 Cost will Remain the Main Challenge

List of Tables

Table 2.1 World Biological Drugs Market: Total Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 2.2 World Biological Drugs Market: Total Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 2.3 Comparative Biological Molecule Sizes

Table 2.4 Top 10 Biological Drugs: Revenues ($m), Market Share (%), 2012

Table 2.5 Top 10 Drugs in the Global Pharmaceutical Market: Revenues ($m), 2012

Table 2.6 Key Therapeutic Areas in the Biologics Market: Revenues ($m), Market Share (%), 2012

Table 2.7 Leading Companies in the Biologics Market: Revenues ($m), Market Share (%), 2012

Table 2.8 Breakdown by Submarket: Revenues ($m), Market Share (%), 2012

Table 2.9 Breakdown by Submarket: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017

Table 2.10 Breakdown by Submarket: Revenues ($m), Market Share (%), 2017

Table 2.11 Breakdown by Submarket: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023

Table 2.12 Breakdown by Submarket: Revenues ($m), Market Share (%), 2023

Table 2.13 Regions of an Antibody

Table 2.14 Natural Antibody Mechanisms of Action

Table 2.15 Potency and Source of Stem Cells

Table 3.1 Protein Therapeutics Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 3.2 Protein Therapeutics Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 3.3 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), Submarket Share (%), 2012

Table 3.4 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%) Submarket Share (%), 2012-2017

Table 3.5 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), Submarket Share (%), 2017

Table 3.6 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023

Table 3.7 Protein Therapeutics Submarket Breakdown by Segment: Revenues ($m), Submarket Share (%), 2023

Table 3.8 EU and US Patent Expiry Dates for Leading Insulins

Table 3.9 Types of Insulin Product, 2013

Table 3.10 Insulins Pipeline: Selected Products, 2013

Table 3.11 Classes of Diabetes Treatments, 2013

Table 3.12 Insulins Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 3.13 Insulins Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 3.14 EU and US Patent Expiry Dates for Leading Erythropoietins

Table 3.15 Other Recombinant Hormones Pipeline: Selected Products, 2013

Table 3.16 Other Recombinant Hormones Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 3.17 Other Recombinant Hormones Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 3.18 Selected Coagulating Factors Significant in Segment R&D, 2013

Table 3.19 Plasma and Recombinant Coagulating Factors Pipeline: Selected Products, 2013

Table 3.20 Plasma and Recombinant Coagulating Factors Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 3.21 Plasma and Recombinant Coagulating Factors Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 3.22 Leading Interferon Products: Revenues ($m), Market Share (%), 2012

Table 3.23 EU and US Patent Expiry Dates for Leading Interferons

Table 3.24 Interferons Pipeline: Selected Products, 2013

Table 3.25 Interferons Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 3.26 Interferons Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 3.27 Other Protein Therapeutics Pipeline: Selected Products, 2013

Table 3.28 Other Protein Therapeutics Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 3.29 Other Protein Therapeutics Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 3.30 Leading Protein Therapeutic Products: Revenues ($m), Submarket Share (%), 2012

Table 3.31 Leading Protein Therapeutic Products: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017

Table 3.32 Leading Protein Therapeutic Products: Revenues ($m), Market Share (%), 2017

Table 3.33 Leading Protein Therapeutic Products: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023

Table 3.34 Leading Protein Therapeutic Products: Revenues ($m), Market Share (%), 2023

Table 3.35 Lantus: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 3.36 Lantus: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 3.37 Neulasta/Neupogen: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 3.38 Neulasta/Neupogen: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 3.39 Epogen: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 3.40 Epogen: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 3.41 Avonex: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 3.42 Avonex: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 3.43 NovoRapid: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 3.44 NovoRapid: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 3.45 Other Products: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 3.46 Other Products: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 3.47 Protein Therapeutics Late-Stage Pipeline, Selected Products, 2013

Table 4.1 Monoclonal Antibodies Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 4.2 Monoclonal Antibodies Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 4.3 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2012

Table 4.4 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%) Market Share (%), 2012-2017

Table 4.5 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2017

Table 4.6 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%) Market Share (%), 2018-2023

Table 4.7 Monoclonal Antibodies Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2023

Table 4.8 Leading Products in Autoimmune MAbs Segment, Revenues ($m), Share of Segment (%), 2012

Table 4.9 Main Molecular Targets in Autoimmune Segment: Revenues ($m), Market Share (%), 2012

Table 4.10 Level of Antibody Humanisation in Autoimmune Segment: Revenues ($m), Market Share (%), 2012

Table 4.11 Leading Companies in Autoimmune Segment: Revenues ($m), Market Share (%), 2012

Table 4.12 Autoimmune MAbs Pipeline: Selected Products, 2013

Table 4.13 RA MAbs Pipeline: Selected Products, 2013

Table 4.14 Asthma MAbs Pipeline: Selected Products, 2013

Table 4.15 Lupus MAbs Pipeline: Selected Products, 2013

Table 4.16 MS MAbs Pipeline: Selected Products, 2013

Table 4.17 Psoriasis MAbs Pipeline: Selected Products, 2013

Table 4.18 Other Autoimmune MAbs Pipeline: Selected Products, 2013

Table 4.19 Autoimmune MAbs Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 4.20 Autoimmune MAbs Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 4.21 Leading Products in Oncology MAbs Segment, Revenues ($m), Share of Segment (%), 2012

Table 4.22 Main Molecular Targets in Oncology Segment: Revenues ($m), Market Share (%), 2012

Table 4.23 Leading Companies in Oncology Segment: Revenues ($m), Market Share (%), 2012

Table 4.24 Oncology MAbs Pipeline: Selected Products, 2013

Table 4.25 Oncology MAbs Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 4.26 Oncology MAbs Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 4.27 Leading Products in Other Therapeutic Areas MAbs Segment, Revenues ($m), Share of Segment (%), 2012

Table 4.28 Other Therapeutic Areas MAbs Pipeline: Selected Products, 2013

Table 4.29 Cardiovascular MAbs Pipeline: Selected Products, 2013

Table 4.30 Alzheimer's Disease MAbs Pipeline: Selected Products, 2013

Table 4.31 Ophthalmic MAbs Pipeline: Selected Products, 2013

Table 4.32 Anti-Infectives MAbs Pipeline: Selected Products, 2013

Table 4.33 Other Therapeutic Areas MAbs Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 4.34 Other Therapeutic Areas MAbs Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 4.35 Leading MAbs: Revenues ($m), Market Share (%), 2012

Table 4.36 Leading MAbs: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017

Table 4.37 Leading MAbs: Revenues ($m), Market Share (%), 2017

Table 4.38 Leading MAbs: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023

Table 4.39 Leading MAbs: Revenues ($m), Market Share (%), 2023

Table 4.40 Humira: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017

Table 4.41 Humira: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023

Table 4.42 Remicade: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017

Table 4.43 Remicade: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023

Table 4.44 Rituxan: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017

Table 4.45 Rituxan: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023

Table 4.46 Herceptin: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017

Table 4.47 Herceptin: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023

Table 4.48 Avastin: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017

Table 4.49 Avastin: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023

Table 4.50 Other MAb Products: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017

Table 4.51 Other MAb Products: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023

Table 4.52 Selected Late-Stage MAbs Pipeline, 2013

Table 5.1 Fusion Proteins Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 5.2 Fusion Proteins Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 5.3 Approved Fusion Proteins, 2013

Table 5.4 Leading Products in Fusion Proteins Segment: Revenues ($m), Market Share (%), 2012

Table 5.5 Fusion Proteins Submarket Leading Products: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017

Table 5.6 Leading Products in Fusion Proteins Segment: Revenues ($m), Market Share (%), 2017

Table 5.7 Fusion Proteins Submarket Leading Products: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023

Table 5.8 Leading Products in Fusion Proteins Segment: Revenues ($m), Market Share (%), 2023

Table 5.9 Enbrel: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017

Table 5.10 Enbrel: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023

Table 5.11 Orencia: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017

Table 5.12 Orencia: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023

Table 5.13 Eylea: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017

Table 5.14 Eylea: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023

Table 5.15 Other Fusion Protein Products: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2012-2017

Table 5.16 Other Fusion Protein Products: Revenues ($m), AGR (%), CAGR (%), Submarket Share (%), 2018-2023

Table 5.17 Fusion Proteins Pipeline: Selected Products, 2013

Table 6.1 Cellular and Regenerative Medicines Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 6.2 Cellular and Regenerative Medicines Submarket: Total Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 6.3 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2012

Table 6.4 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%) Market Share (%), 2012-2017

Table 6.5 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2017

Table 6.6 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%) Market Share (%), 2018-2023

Table 6.7 Cellular and Regenerative Medicines Submarket Breakdown by Segment: Revenues ($m), Market Share (%), 2023

Table 6.8 Tissue Engineered Products Pipeline: Selected Products, 2013

Table 6.9 Tissue Engineered Products Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 6.10 Tissue Engineered Products Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 6.11 Cellular Therapies Pipeline: Selected Products, 2013

Table 6.12 Cellular Therapies Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 6.13 Cellular Therapies Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 6.14 Gene Therapy Pipeline: Selected Products, 2013

Table 6.15 Gene Therapy Segment: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 6.16 Gene Therapy Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2023

Table 6.17 Cellular and Other Regenerative Medicines Submarket: Selected Late-Stage Pipeline, 2013

Table 7.1 Regional Breakdown of the Biological Drugs Market, Revenues ($m), Market Shares (%), 2012

Table 7.2 Regional Breakdown of the Biological Drugs Market: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2012-2017

Table 7.3 Regional Breakdown of the Biological Drugs Market, Revenues ($m), Market Shares (%) 2017

Table 7.4 Regional Breakdown of the Biological Drugs Market: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2018-2023

Table 7.5 Regional Breakdown of the Biological Drugs Market, Revenues ($m), Market Shares (%), 2023

Table 7.6 US: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017

Table 7.7 US: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023

Table 7.8 EU5: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017

Table 7.9 EU5: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023

Table 7.10 National Breakdown of the EU5, Revenues ($m), Share of Market (%), 2012

Table 7.11 National Breakdown of the EU5, Revenues ($m), AGR (%), CAGR (%), Share of Market (%), 2012-2017

Table 7.12 National Breakdown of the EU5, Revenues ($m), Share of Market (%), 2017

Table 7.13 National Breakdown of the EU5, Revenues ($m), AGR (%), CAGR (%), Share of Market (%), 2018-2023

Table 7.14 National Breakdown of the EU5, Revenues ($m), Share of Market (%) 2023

Table 7.15 Japan: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017

Table 7.16 Japan: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023

Table 7.17 BRIC Nations: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017

Table 7.18 BRIC Nations: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2023

Table 7.19 National Breakdown of the BRIC Nations, Revenues ($m), Share of Market (%) 2012

Table 7.20 National Breakdown of the BRIC Nations, Revenues ($m), AGR (%), CAGR (%), Share of Market (%), 2012-2017

Table 7.21 National Breakdown of the BRIC Nations, Revenues ($m), Share of Market (%), 2017

Table 7.22 National Breakdown of the BRIC Nations, Revenues ($m), AGR (%), CAGR (%), Share of Market (%), 2018-2023

Table 7.23 National Breakdown of the BRIC Nations, Revenues ($m), Share of Market (%), 2023

Table 8.1 World Biologics Market: Strengths and Weaknesses, 2013

Table 8.2 World Biologics Market: Opportunities and Threats, 2013

Table 8.3 World Biologics Market: STEP Analysis, 2013-2023

List of Figures

Figure 2.1 World Biological Drugs Market: Total Revenues ($m), 2012-2023

Figure 2.2 Comparative Biological Molecule Sizes

Figure 2.3 Biologics Market as Sector Within the Global Pharmaceuticals Market: Revenues ($bn), Market Share (%), 2012

Figure 2.4 Top 10 Biological Drugs: Revenues ($m), Market Share (%), 2012

Figure 2.5 Top 10 Drugs in the Global Pharmaceutical Mark

Read the full report:

World Biological Drugs Market 2013-2023

http://www.reportbuyer.com/pharma_healthcare/therapeutic/world_biological_drugs_market_2013_2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: http://www.reportbuyer.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/10/prweb11279599.htm


Source: prweb



comments powered by Disqus